Bicycle Therapeutics Announces Results of 2026 Annual General Meeting of Shareholders

Bicycle Therapeutics plc held its Annual General Meeting (AGM) of shareholders on June 17, 2026. During the meeting, shareholders voted on and approved several key proposals. This included the re-election of Felix Baker and Hervé Hoppenot to the Board of Directors. Shareholders also approved, on an advisory basis, the compensation of the company's named executive officers and the directors' remuneration report for the year ended December 31, 2025. Additionally, the directors' remuneration policy was approved and became effective immediately following the AGM. The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026 and as U.K. statutory auditors was ratified. Shareholders also authorized the Audit Committee to determine the auditors' remuneration. Finally, the company's U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2025, were received and adopted. Approximately 98.64% of the issued and outstanding ordinary shares were represented at the meeting.